Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst ...

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilum ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Sanofi’s U.S.-listed shares plunged more than 6% in premarket trading by 08:03 GMT, while Regeneron fell over 8%. In one study involving former smokers with uncontrolled chronic obstructive pulmonary ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Regeneron jumped 8.6% in U.S. premarket trade and was set to open at a record high. “COPD is an urgent global health concern and a notoriously difficult-to-treat disease due to its heterogeneity, with ...